If I could just add, the general issue of administrative burden for health care practitioners is a significant one, particularly in the pharmacy sector, where we have to deal with significant administrative loads around both public and private drug plans. Certainly at the time that PIPEDA was drafted, because of the vagueness of the legislation, we were very concerned about what the administrative burden was likely to be. Hence they asked for delaying it substantially, until we could get more specific information around health care.
In practice, again echoing what my colleagues have said, the PARTs guidelines have been very critical in allowing that burden to be manageable.
But again, in every provincial jurisdiction, each with its own privacy legislation, pharmacies in those provinces have obviously had to comply with that. But usually this has been recognized as being substantially similar, so less of a burden.